Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Polymorphisms of cytokine genes and tuberculosis in two independent studies on February 22, 2019 at 1:36 am
Linkage disequilibrium (LD) of cytokine gene SNPs in the both Han (above) and Tibetan (below) populations. LD r2 values (ranging from 0 to 1) for all pairs of SNPs are presented as percentages. Shadin... […]
- Tuberculosis patients more likely to continue treatment administered via smartphone app on February 21, 2019 at 3:30 pm
Tuberculosis (TB) patients are more likely to continue drug treatment administered over smartphone than through face-to-face appointments, a study has found. Researchers from University College London ... […]
- IDRI partners with Afrigen Biologics and Biovac to produce tuberculosis vaccine on February 21, 2019 at 1:24 pm
In an effort to produce vaccines where they are needed most, IDRI (Infectious Disease Research Institute) is collaborating with the Cape Town, South Africa, based biotechnology startup company Afrigen ... […]
- University of Missouri reports tuberculosis case on campus on February 19, 2019 at 11:43 am
COLUMBIA, Mo. (AP) — The University of Missouri says a student has been diagnosed with active tuberculosis and left campus voluntarily. The school said in a news release that campus and local health o... […]
- Mizzou student voluntarily leaves campus after contracting tuberculosis on February 18, 2019 at 8:12 pm
COLUMBIA, MO (KFVS) - Officials at the University of Missouri say that a student has voluntarily left campus after being diagnosed with active tuberculosis. According to a news release, the University ... […]
- Student diagnosed with active tuberculosis at University of Missouri on February 18, 2019 at 7:28 pm
Feb. 18--COLUMBIA, Mo. — University of Missouri officials announced Monday that a student has been diagnosed with active tuberculosis. Load Error The university said the student has voluntarily left t... […]
- Researchers identify suicide toxin in the bacteria responsible for tuberculosis on February 18, 2019 at 6:50 pm
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein. The European team of scientists behind this discovery is coordinated by ... […]
- MU student diagnosed with tuberculosis, university says on February 18, 2019 at 5:24 pm
The University of Missouri announced Monday that a student was diagnosed with active tuberculosis. School officials said the student voluntarily left campus.The university is working with doctors and ... […]
- MU student diagnosed with tuberculosis on February 18, 2019 at 1:35 pm
COLUMBIA — An unidentified MU student has been diagnosed with active tuberculosis, the university confirmed in a news release on Monday. The student has voluntarily left campus. "The student has been ... […]
- Missouri student on Columbia campus has active tuberculosis on February 18, 2019 at 1:20 pm
COLUMBIA, Mo. (AP) — University of Missouri officials say a student on the Columbia campus has active tuberculosis and may have infected other people. The school announced Monday that the Boone County ... […]
via Bing News